Email updates

Keep up to date with the latest news and content from Virology Journal and BioMed Central.

Open Access Highly Accessed Review

Porcine circovirus type 2 in China: an update on and insights to its prevalence and control

Shao-Lun Zhai12, Sheng-Nan Chen3, Zhi-Hong Xu2, Man-Hua Tang3, Feng-Guo Wang3, Xiao-Jing Li3, Bei-Bei Sun1, Su-Fang Deng1, Jun Hu1, Dian-Hong Lv2, Xiao-Hui Wen2, Jie Yuan2, Man-Lin Luo1* and Wen-Kang Wei2*

Author Affiliations

1 College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China

2 Institute of Animal Health, Guangdong Academy of Agricultural Sciences, No. 21 Baishigang Street, Wushan Road, Tianhe District, Guangzhou 510640, China

3 Guangdong Dahuanong Animal Health Products Co., Ltd., Xinxing 527400, Yunfu, China

For all author emails, please log on.

Virology Journal 2014, 11:88  doi:10.1186/1743-422X-11-88

Published: 14 May 2014

Abstract

Currently, porcine circovirus type 2 (PCV2) is considered the major pathogen of porcine circovirus associated-diseases (PCVAD) that causes large economic losses for the swine industry in the world annually, including China. Since the first report of PCV2 in 1998, it has been drawing tremendous attention for the government, farming enterprises, farmers, and veterinary practitioners. Chinese researchers have conducted a number of molecular epidemiological work on PCV2 by molecular approaches in the past several years, which has resulted in the identification of novel PCV2 genotypes and PCV2-like agents as well as the description of new prevalence patterns. Since late 2009, commercial PCV2 vaccines, including the subunit vaccines and inactivated vaccines, have already been used in Chinese swine farms. The aim of this review is to update the insights into the prevalence and control of PCV2 in China, which would contribute to understanding the epidemiology, control measures and design of novel vaccines for PCV2.

Keywords:
Porcine circovirus type 2; Prevalence; Control; PCV2 vaccines; Update; China